Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the associ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schneider, Bryan P., Wang, Molin, Radovich, Milan, Sledge, George W., Badve, Sunil, Thor, Ann, Flockhart, David A., Hancock, Bradley, Davidson, Nancy, Gralow, Julie, Dickler, Maura, Perez, Edith A., Cobleigh, Melody, Shenkier, Tamara, Edgerton, Susan, Miller, Kathy D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653128/
https://ncbi.nlm.nih.gov/pubmed/18824714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.1612
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados